Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine

C. T. Weyer, J. D. Grewar, P. Burger, C. Joone, C. Lourens, Nigel J Maclachlan, A. J. Guthrie

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

African horse sickness (AHS) is a fatal disease of equids relevant to the global equine industry. Detection of AHS virus (AHSV) during outbreaks has become more rapid and efficient with the advent of group specific reverse transcriptase quantitative polymerase chain reaction (GS RT-qPCR) assays to detect AHSV nucleic acid. Use of GS RT-qPCR together with recently described type specific (TS RT-qPCR) assays cannot only expedite diagnosis of AHS but also facilitate further evaluation of the dynamics of AHSV infection in the equine host. A potential limitation to the application of these assays is that they detect viral nucleic acid originating from any AHS live attenuated vaccine (LAV), which is the vaccine type routinely administered to horses in South Africa. The aim of this study was to contrast the dynamics and duration of the RNAaemia to the serological responses of horses following immunization with a commercial polyvalent AHSV-LAV using GS and TS RT-qPCR assays and serum neutralisation tests. The results of the study showed extended RNAemia in vaccinated horses, and that more horses tested positive on GS RT-qPCR with lower Cq values after receiving the AHSV-LAV containing types 1, 3 and 4 prior to the vaccine containing types 2, 6, 7 and 8, rather than when the vaccine combinations were reversed. Furthermore, lower Cq values were obtained when vaccines were administered 4 weeks apart as compared with a longer interval or 12 weeks apart. These findings are of particular relevance in regions where AHSV-LAVs are used as the use of these vaccines may complicate the accurate interpretation of diagnostic testing results.

Original languageEnglish (US)
Pages (from-to)2504-2510
Number of pages7
JournalVaccine
Volume35
Issue number18
DOIs
StatePublished - Apr 25 2017

Fingerprint

African Horse Sickness Virus
African horse sickness virus
Attenuated Vaccines
live vaccines
Nucleic Acids
nucleic acids
Horses
Immunization
African Horse Sickness
immunization
African horse sickness
horses
antibodies
Antibodies
vaccines
Vaccines
viruses
Reverse Transcriptase Polymerase Chain Reaction
Viruses
quantitative polymerase chain reaction

Keywords

  • AHSV
  • Live attenuated vaccine
  • RNAemia

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine. / Weyer, C. T.; Grewar, J. D.; Burger, P.; Joone, C.; Lourens, C.; Maclachlan, Nigel J; Guthrie, A. J.

In: Vaccine, Vol. 35, No. 18, 25.04.2017, p. 2504-2510.

Research output: Contribution to journalArticle

Weyer, C. T. ; Grewar, J. D. ; Burger, P. ; Joone, C. ; Lourens, C. ; Maclachlan, Nigel J ; Guthrie, A. J. / Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine. In: Vaccine. 2017 ; Vol. 35, No. 18. pp. 2504-2510.
@article{84796bf6b1ee4131af53be8ef9302e63,
title = "Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine",
abstract = "African horse sickness (AHS) is a fatal disease of equids relevant to the global equine industry. Detection of AHS virus (AHSV) during outbreaks has become more rapid and efficient with the advent of group specific reverse transcriptase quantitative polymerase chain reaction (GS RT-qPCR) assays to detect AHSV nucleic acid. Use of GS RT-qPCR together with recently described type specific (TS RT-qPCR) assays cannot only expedite diagnosis of AHS but also facilitate further evaluation of the dynamics of AHSV infection in the equine host. A potential limitation to the application of these assays is that they detect viral nucleic acid originating from any AHS live attenuated vaccine (LAV), which is the vaccine type routinely administered to horses in South Africa. The aim of this study was to contrast the dynamics and duration of the RNAaemia to the serological responses of horses following immunization with a commercial polyvalent AHSV-LAV using GS and TS RT-qPCR assays and serum neutralisation tests. The results of the study showed extended RNAemia in vaccinated horses, and that more horses tested positive on GS RT-qPCR with lower Cq values after receiving the AHSV-LAV containing types 1, 3 and 4 prior to the vaccine containing types 2, 6, 7 and 8, rather than when the vaccine combinations were reversed. Furthermore, lower Cq values were obtained when vaccines were administered 4 weeks apart as compared with a longer interval or 12 weeks apart. These findings are of particular relevance in regions where AHSV-LAVs are used as the use of these vaccines may complicate the accurate interpretation of diagnostic testing results.",
keywords = "AHSV, Live attenuated vaccine, RNAemia",
author = "Weyer, {C. T.} and Grewar, {J. D.} and P. Burger and C. Joone and C. Lourens and Maclachlan, {Nigel J} and Guthrie, {A. J.}",
year = "2017",
month = "4",
day = "25",
doi = "10.1016/j.vaccine.2017.03.005",
language = "English (US)",
volume = "35",
pages = "2504--2510",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "18",

}

TY - JOUR

T1 - Dynamics of African horse sickness virus nucleic acid and antibody in horses following immunization with a commercial polyvalent live attenuated vaccine

AU - Weyer, C. T.

AU - Grewar, J. D.

AU - Burger, P.

AU - Joone, C.

AU - Lourens, C.

AU - Maclachlan, Nigel J

AU - Guthrie, A. J.

PY - 2017/4/25

Y1 - 2017/4/25

N2 - African horse sickness (AHS) is a fatal disease of equids relevant to the global equine industry. Detection of AHS virus (AHSV) during outbreaks has become more rapid and efficient with the advent of group specific reverse transcriptase quantitative polymerase chain reaction (GS RT-qPCR) assays to detect AHSV nucleic acid. Use of GS RT-qPCR together with recently described type specific (TS RT-qPCR) assays cannot only expedite diagnosis of AHS but also facilitate further evaluation of the dynamics of AHSV infection in the equine host. A potential limitation to the application of these assays is that they detect viral nucleic acid originating from any AHS live attenuated vaccine (LAV), which is the vaccine type routinely administered to horses in South Africa. The aim of this study was to contrast the dynamics and duration of the RNAaemia to the serological responses of horses following immunization with a commercial polyvalent AHSV-LAV using GS and TS RT-qPCR assays and serum neutralisation tests. The results of the study showed extended RNAemia in vaccinated horses, and that more horses tested positive on GS RT-qPCR with lower Cq values after receiving the AHSV-LAV containing types 1, 3 and 4 prior to the vaccine containing types 2, 6, 7 and 8, rather than when the vaccine combinations were reversed. Furthermore, lower Cq values were obtained when vaccines were administered 4 weeks apart as compared with a longer interval or 12 weeks apart. These findings are of particular relevance in regions where AHSV-LAVs are used as the use of these vaccines may complicate the accurate interpretation of diagnostic testing results.

AB - African horse sickness (AHS) is a fatal disease of equids relevant to the global equine industry. Detection of AHS virus (AHSV) during outbreaks has become more rapid and efficient with the advent of group specific reverse transcriptase quantitative polymerase chain reaction (GS RT-qPCR) assays to detect AHSV nucleic acid. Use of GS RT-qPCR together with recently described type specific (TS RT-qPCR) assays cannot only expedite diagnosis of AHS but also facilitate further evaluation of the dynamics of AHSV infection in the equine host. A potential limitation to the application of these assays is that they detect viral nucleic acid originating from any AHS live attenuated vaccine (LAV), which is the vaccine type routinely administered to horses in South Africa. The aim of this study was to contrast the dynamics and duration of the RNAaemia to the serological responses of horses following immunization with a commercial polyvalent AHSV-LAV using GS and TS RT-qPCR assays and serum neutralisation tests. The results of the study showed extended RNAemia in vaccinated horses, and that more horses tested positive on GS RT-qPCR with lower Cq values after receiving the AHSV-LAV containing types 1, 3 and 4 prior to the vaccine containing types 2, 6, 7 and 8, rather than when the vaccine combinations were reversed. Furthermore, lower Cq values were obtained when vaccines were administered 4 weeks apart as compared with a longer interval or 12 weeks apart. These findings are of particular relevance in regions where AHSV-LAVs are used as the use of these vaccines may complicate the accurate interpretation of diagnostic testing results.

KW - AHSV

KW - Live attenuated vaccine

KW - RNAemia

UR - http://www.scopus.com/inward/record.url?scp=85015805386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015805386&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2017.03.005

DO - 10.1016/j.vaccine.2017.03.005

M3 - Article

C2 - 28341113

AN - SCOPUS:85015805386

VL - 35

SP - 2504

EP - 2510

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 18

ER -